Loading…
Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients
Background Cancer immunotherapy has had an important role in oncologic therapeutics for patients with non‐small cell lung cancer (NSCLC) using checkpoint inhibitors. We will explore the possible prognosis biomarker candidates such as: soluble OX40 (sOX40), OX40L (sOX40L), Glucocorticoid‐induced tumo...
Saved in:
Published in: | Journal of surgical oncology 2024-09, Vol.130 (4), p.919-928 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Cancer immunotherapy has had an important role in oncologic therapeutics for patients with non‐small cell lung cancer (NSCLC) using checkpoint inhibitors. We will explore the possible prognosis biomarker candidates such as: soluble OX40 (sOX40), OX40L (sOX40L), Glucocorticoid‐induced tumor necrosis factor receptor family‐related receptor (GITR), and their ligand (GITRL), 4‐1BB or tumor necrosis factor receptor superfamily 9 (TNFRS9) and inducible T cell co‐stimulator (ICOS) in peripheral blood of NSCLC patients.
Methods
Fifty‐eight patients were diagnosed with advanced NSCLC between January 2019 and March 2020.
Results
High sOX40 and low s4‐1BB levels in smokers compared non‐smoker NSCLC patients. Lower sOX40L levels were found in the male than female (p |
---|---|
ISSN: | 0022-4790 1096-9098 1096-9098 |
DOI: | 10.1002/jso.27763 |